GRCL News and Press, Gracell Biotechnologies Inc. From 12/21/23

Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in rSLE, aiming for deeper and wider depletion of disease-causing antibody secreting cells and B-ce...

Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months GC012F is a FasTCAR-enabled B-cell maturation antigen (BCMA) and CD19 dual-targeting a...

2023-12-03 04:30:00 ET Summary LianBio, a Princeton-Shanghai in-licensing company, received a $465 million buyout offer from Tang Capital Management. Perpetual Medicines, a Shanghai-Boston AI startup, closed an $8 million seed financing to advance its peptide drug discovery platfo...

2023-11-27 13:29:09 ET More on Gracell Biotechnologies Gracell Biotechnologies Inc. (GRCL) Q3 2023 Earnings Call Transcript Gracell Biotechnologies: A CAR-T Company Flying Under Your Radar Gracell Biotechnologies Q3 GAAP EPS of -$0.51 misses by $0.38 Gracell ...

Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells and B-cells FasTCAR-T GC012F has demonstrated deep responses and a favorable safety pro...

2023-11-24 09:46:18 ET More on Health Care Select Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employment ...

Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease Gracell to highlight translational research supporting CD19/BCMA dual-targeting approach in the treatment of systemic lupus erythematosus (SLE) SAN DIEGO and S...

2023-11-13 20:50:08 ET Gracell Biotechnologies Inc. (GRCL) Q3 2023 Earnings Conference Call November 13, 2023, 08:00 AM ET Company Participants William Cao - Chairman and CEO Wendy Li - Chief Medical Officer Kevin Xie - CFO Conference Call Participants ...

2023-11-13 10:50:32 ET More on Gracell Biotechnologies Gracell Biotechnologies: A CAR-T Company Flying Under Your Radar Gracell draws Buy at Stifel on upcoming readout for lead asset Seeking Alpha’s Quant Rating on Gracell Biotechnologies Historical ea...

Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) Expect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the fourth quarter 2023 Prese...